Simplifying a complex
Advancing patient care with
As a pioneer in the field, Mayo Clinic plays an integral role by developing new tests to help align patients with new therapies for plasma cell disorders. Our algorithmic approach ensures that the right tests are ordered at the right time, and that health care providers get clinically actionable answers for their patients faster. And testing with Mayo Clinic means 24/7 access to our physician and laboratory experts, who are leaders in their fields
With you Every Step of the Way
A groundbreaking method to accurately identify
monoclonal proteins and determine risk of progression.
Diagnosis and Risk Stratification
A simplified approach to risk stratification and
diagnosis using the Mayo Stratification for
Myeloma and Risk-Adapted Therapy (mSMART).
Accurate monitoring of patients to determine
response to therapy and risk of relapse.
Breaking down the facts
When a patient presents with a monoclonal protein (M protein) disorder, the answer is not always multiple myeloma. From the more common diagnosis of monoclonal gammopathy of undetermined significance (MGUS), to rarer findings such as AL amyloidosis or POEMS syndrome, plasma cell neoplasms are increasingly recognized as more than one disease and characterized by marked protein, cytogenetic, molecular, and proliferative heterogeneity. Clinicians are increasingly challenged to provide answers in this rapidly changing environment. Advances in testing methodologies, novel therapies, and individualized treatment regimens continually add to the complexity of treating patients. Whether you’re screening, diagnosing, or monitoring patients, we offer leading-edge testing while keeping patient care local.
How an Ex-NFL Linebacker Overcame his Greatest Opponent, Amylodosis
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.